CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
News|Articles|March 1, 2005
Ziprasidone and risperidone equally efficacious for treatment of acute exacerbation of schizophrenia or schizoaffective disorder
Ziprasidone (Geodon, Pfizer) and risperidone (Risperdal, Janssen) are equally efficacious in the treatment of patients with acute exacerbation of schizophrenia and schizoaffective disorder, with ziprasidone demonstrating a lower movement disorder burden and less effect on prolactin concentrations and weight than risperidone.
Advertisement
Advertisement
Related to this article
A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability
Pharmacy benefit managers are moving beyond formulary access to provide support programs for women's health. Here's how three PBMs — Judi Health, LucyRx and RxPreferred — are putting that strategy into practice.
Women face more gaps in healthcare than men, from missed screenings, undertreatment and biased coverage. PBMs are launching programs to address some of the gaps.
Dunn of NeosRx says a 340B shift from discounts to rebates likely won't affect rebate erosion affecting plan sponsors.
Five transcranial magnetic stimulation sessions in one day improved processing speed in adults with schizophrenia, which holds promise for future treatment possibilities, according to researcher Heather Burrell Ward, M.D.
Imaging has been associated with four of the five most prevalent low-value services among Medicare beneficiaries.
One of teledentistry's most valuable applications is triage — helping a patient understand whether a concern can wait for an appointment, requires prompt attention or warrants emergency medical care.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Texas A&M researchers discover promising therapy for fatty liver disease
2
The hidden costs of routine radiology and how they can be addressed
3
Jeff Dunn, Pharm.D., MBA, on 340B rebates vs. discounts — and transparency | PBMI 2026
4
FDA approves Lilly’s Onswik, the second once-weekly insulin
5